dChan
Anonymous ID: cf975c June 13, 2021, 7:49 a.m. No.13892740   🗄️.is đź”—kun

"Died from Covid, not the Shot…

It's never the SHOT though…

 

8 fully vaccinated Mainers have died from COVID-19. Vaccines still prevent more deaths.

 

Jun. 13—When Karen Letourneau saw her mother in April for the first time in more than a year, she did not expect it would be the last time.

 

Three weeks earlier, Letourneau's mother, Patricia Caron of Lewiston, had received the Johnson & Johnson vaccine.The day they met, Caron felt symptoms of what she thought was a cold. But when Letourneau, who lives in Wales and was partially vaccinated then, found herself experiencing COVID-19 symptoms a few days later, she asked her mother to get tested.

 

Caron got a rapid coronavirus test. It came back positive. She ended up in the hospital and died of COVID-19 complications a few weeks later, her daughter said, becoming one of eight fully vaccinated Mainers to succumb to the disease.

 

These so-called breakthrough infections are rare, Maine Center for Disease Control and Prevention Director Nirav Shah said last week. The state has identified 426 cases of the virus in fully vaccinated people, accounting for about 1 of every 1,600 vaccinated people in Maine. By comparison, more than 15,000 Mainers, or 1 out of every 88 people, have tested positive for the virus in the past two months alone.

 

Those numbers fit with scientific studies showing the vaccines used in the U.S. are more than 90 percent effective. But the deaths are tragedies for families who assumed vaccines would eliminate COVID-19 risk and raise concerns among people with compromised immune systems and their loved ones.

 

Health officials still emphasize that vaccinations are still the best way to stop the spread of the virus and prevent severe disease and are optimistic that Maine's high overall vaccination rate will continue to reduce transmission, including breakthrough cases.

 

The initial data suggest breakthrough cases in Maine are more common in older individuals and people with underlying health conditions, Shah said. Almost all are not serious. About half of vaccinated people who tested positive for COVID-19 were not experiencing symptoms when contacted by a case investigator, according to the Maine CDC. Only 19 have been hospitalized.

 

Importantly, breakthrough cases have not been associated with one COVID-19 vaccine more than others, Shah said, nor have they been linked to particular variants. He said people who tested positive for the virus after being vaccinated were exposed in a variety of ways.

 

Because vaccines work by stimulating an immune response, they can be less effective for those with weakened immune systems, such as organ transplant recipients or chemotherapy patients, said Dr. James Jarvis, who leads Northern Light Health's COVID-19 response.

 

more bs

https://www.yahoo.com/news/8-fully-vaccinated-mainers-died-132800039.html

Anonymous ID: cf975c June 13, 2021, 8:17 a.m. No.13892937   🗄️.is đź”—kun

>>13892884

Moderna Wins Initial $20M Grant from Gates Foundation

 

https://www.genengnews.com/topics/omics/moderna-wins-initial-20m-grant-from-gates-foundation/

 

Then, in October, the government's Defense Advanced Research Projects Agency (DARPA) awarded Moderna $25 million to develop mRNA to combat infectious diseases and biological threats.

 

https://www.alumni.hbs.edu/stories/Pages/story-bulletin.aspx?num=3170

 

Removing the Viral Threat: Two Months to Stop Pandemic X from Taking Hold

 

DARPA aims to develop an integrated end-to-end platform that uses nucleic acid sequences to halt the spread of viral infections in sixty days or less

 

OUTREACH@DARPA.MIL 2/6/2017

 

Over the past several years, DARPA-funded researchers have pioneered RNA vaccine technology, a medical countermeasure against infectious diseases that uses coded genetic constructs to stimulate production of viral proteins in the body, which in turn can trigger a protective antibody response. As a follow-on effort, DARPA funded research into genetic constructs that can directly stimulate production of antibodies in the body.1,2 DARPA is now launching the Pandemic Prevention Platform (P3) program, aimed at developing that foundational work into an entire system capable of halting the spread of any viral disease outbreak before it can escalate to pandemic status. Such a capability would offer a stark contrast to the state of the art for developing and deploying traditional vaccines—a process that does not deliver treatments to patients until months, years, or even decades after a viral threat emerges.

 

“DARPA’s goal is to create a technology platform that can place a protective treatment into health providers’ hands within 60 days of a pathogen being identified, and have that treatment induce protection in patients within three days of administration. We need to be able to move at this speed considering how quickly outbreaks can get out of control,” said Matt Hepburn, the P3 Program Manager. “The technology needs to work on any viral disease, whether it’s one humans have faced before or not.”

 

Recent outbreaks of viral infectious diseases such as Zika, H1N1 influenza, and Ebola have cast into sharp relief the inability of the global health system to rapidly contain the spread of a disease using existing tools and procedures. State-of-the-art medical countermeasures typically take many months or even years to develop, produce, distribute, and administer. These solutions often arrive too late—if at all—and in quantities too small to respond to emerging threats. In contrast, the envisioned P3 platform would cut response time to weeks and stay within the window of relevance for containing an outbreak.

 

more

 

https://www.darpa.mil/news-events/2017-02-06a